Emerging BioTalk
  • Home
  • About Us
  • Contact
  • Search
  • Menu

Assembling a new gene therapy company to develop the next generation of pioneering medicines

July 25, 2021/in Uncategorized /by Multiple Authors

Having both recently graduated from our Masters degrees, Christina in Neuroscience from ETH Zürich and Charlotte in Chemistry from The University of Edinburgh, our first days at VectorY were certainly puzzling; new faces, busy schedules, lots to learn and lots to do. Since VectorY is a start-up, founded in October 2020, we are not the only new additions to the company. For us, both Junior Technicians, and the least experienced members of the team, building up our understanding of VectorY has been like putting together the pieces of a jigsaw having never seen the final image on the puzzle box. Supported by the team of highly skilled experts: molecular and structural biologists, protein chemists, immunologists, virologists, translational scientists and process engineers, who together bring many years of combined industry and research knowledge, it has been possible for us to apprehend the goals and mission of VectorY.

VectorY is an Amsterdam based gene therapy company specialising in the development of vectorized antibodies to treat diseases of high unmet medical need, with a specific focus on muscle and neuromuscular diseases. Despite the limited number of approved gene therapies, progress within the field has been remarkable over the past few years and many new companies have emerged. It is therefore not unreasonable to ask, what makes VectorY stand out from the rest? In rethinking our approach to the development of gene therapy treatments we have established three integrated pillars on top of which the company was founded by a group of gene therapy enthusiasts and Forbion, a leading European venture capital firm, as the founding investor.

The first of these pillars is research. This department works on disease-targeting and the development of innovative vectorized antibodies, pushing the limits of current therapies in terms of delivery, durability and target accessibility. The second pillar is vector development, where vehicles to deliver the therapy developed by the research team are constructed and optimized. The aim of the vector development team is to target different cell types and sub-cellular compartments in a highly specific manner whilst evading the host immune response. The final pillar, manufacturing, focuses on advanced manufacturing technologies for the cost effective production and scale up of viral vectors. We also intend to build a manufacturing facility where our gene therapies will be produced using optimized production processes resulting in shorter timelines and lower cost of goods.

One fundamental aspect of the VectorY model is to establish a facility with dedicated laboratories rather than operating as a virtual company and contracting out large amounts of work. This allows for reduced timelines and greater control over our research and processes ensuring we continue to drive development in the right direction. Early investment in manufacturing also helps to minimize longer term risks associated with potential capacity shortages. In addition to this, by gathering a team of experts on site we strive to foster innovation. Social distancing measures have made cultivating a sense of community between the team more challenging than in pre-pandemic times. Creative alternatives to team building activities, such as our game of online bingo, have been adopted and enjoyed, strengthening a spirit of collaboration within the team.

Start-ups must always navigate many obstacles but launching a biotech company in the midst of a pandemic has presented many unique challenges.  From identifying where to install new power sockets to removing fume hoods, coordinating such activities has been an expected, though entirely new undertaking for the team. Of paramount importance was the implementation of a system to account for the great quantities of packages arriving every day, sometimes filling the lift from floor to ceiling. As the labs have filled with equipment and consumables, keeping track of what is on site, what is incoming and what is still needed has been an enormous undertaking. Where the classical start-up lifecycle starts in a single workspace, we got a head start by having access to multiple laboratories and offices at our disposal. Notably, within six months our previously empty labs and offices have been transformed into fully operational offices and laboratories with the latest technologies needed for scientific discovery.

Furthermore, due to the pandemic and unfortunate global supply chain disruptions, much of the equipment and consumables we use in our processes are in high demand, resulting in long lead times. The pipette tips that are an essential component of virtually every experiment we do are also crucial disposables for the huge numbers of Covid-19 tests being carried out worldwide. The material used in the production of these tips, as well as various tubes used for experiments, has also proven hard to obtain due in part to incredibly high demand but also as a result of extreme weather conditions impacting production at a major manufacturing site in the U.S. In addition to this, securing the bioprocess equipment and consumables we require to run our 50 L pilot scale process has been more challenging than in pre-pandemic times. This equipment is used to manufacture Covid-19 vaccines and lead times can be upwards of six months. Sourcing vital equipment can, at times, feel like we are assembling a jigsaw whose pieces are scattered across the entire world.

Despite the difficulties associated with start-ups, and the additional hurdles presented by the pandemic, we continue to make steps towards our goals and this is truly exciting. Additional support provided by

Merck
MilliporeSigma
has provided us with valuable insight on topics ranging from cell media to bioprocessing equipment and consumables expertise and we are delighted to have been awarded the
Merck Millipore Advance Biotech Grant for 2021
MilliporeSigma Advance Biotech Grant for 2021
. This support has aided in our rapid growth and helped us integrate as a new organization into the life sciences space. Ultimately, our goal is to deliver the best science to meet the needs of patients. If the pandemic has taught us one thing it is that mountains can be moved when many minds work together towards a common goal. We hope that in the coming years we can solve the puzzle of developing therapeutics for disease areas of high unmet medical need, and that life changing treatments can be delivered to patients all over the world.

 

References: 

VectorY website: https://www.vectorytx.com/

Launch of VectorY, press release: https://www.vectorytx.com/press-releases

With a roster of gene therapy vets, Forbion makes a bet on ‘relatively empty space’ of vectorized antibodies, February 10, 2021 (Endpoints article): https://endpts.com/with-a-roster-of-gene-therapy-vets-forbion-makes-a-bet-on-relatively-empty-space-of-vectorized-antibodies/

Forbion website: https://forbion.com/en/

Launch of novel gene therapy company, VectorY, to develop innovative vectorized antibodies, February 10, 2021:

https://forbion.com/en/news/launch_of_novel_gene_therapy_company_vectory_to_develop_innovative_vectorized_antibodies#:~:text=Amsterdam%2C%20The%20Netherlands%20%E2%80%93%2010%20February,for%20muscular%20and%20neurodegenerative%20disorders

The Latest Supply Chain Disruption: Plastics, March 26, 2021: https://hbr.org/2021/03/the-latest-supply-chain-disruption-plastics

Merck Announces VectorY as Winner of its Advance Biotech Grant. May 18, 2021:

https://www.merckmillipore.com/NL/en/20210517_173115?ReferrerURL=https%3A%2F%2Fwww.google.com%2F

VectorY at ASGCT 2021: https://www.vectorytx.com/news/vectory-presents-at-asgct-2021

 

  • Author
  • Recent Posts
Christina Maat
Junior Technician at VectorY
Christina is a Junior Technician at VectorY working in the vector development team. After having worked as a research assistant on human post mortem brain pathology (at the Amsterdam UMC), she continued studying the brain in a more mechanistic way during her Master’s in Biology at ETH Zürich in Switzerland. At VectorY, Christina supports the vector development team in advancing the application of biological mechanisms, for developing effective gene therapies. Her active lifestyle and curious nature match the diverse places in which she has lived. While she reminisces hiking the Swiss Alps or exploring California’s coastline, forests and mountains ranges, biking through the city of Amsterdam on a sunny day feels equally great!
Latest posts by Christina Maat (see all)
    • Author
    • Recent Posts
    Charlotte McLure
    Junior Technician at VectorY
    Charlotte is a Junior Technician at VectorY working in the process development team. Her background is in Chemistry and she holds a Master’s in Chemistry with Environmental and Sustainable Chemistry from The University of Edinburgh. The life-sciences world is therefore new to Charlotte, but she has thoroughly enjoyed building up her understanding of gene therapy and of bioprocessing. Originally from Scotland, she loves to ski and to mountain bike. Upon arrival in the flattest country in Europe, she swapped her mountain bike for a race bike and enjoys exploring The Netherlands at great speed in this way. In her free time she likes to dance at festivals and to talk about her cat.
    Latest posts by Charlotte McLure (see all)
      +3
      Share this entry
      • Share on Facebook
      • Share on Twitter
      • Share on LinkedIn
      • Share by Mail
      http://emergingbiotalk.com/wp-content/uploads/2021/07/Picture-1.jpg 575 766 Multiple Authors http://emergingbiotalk.com/wp-content/uploads/2020/05/emergingbiotalk-header.png Multiple Authors2021-07-25 11:46:322021-09-01 08:45:21Assembling a new gene therapy company to develop the next generation of pioneering medicines

      Biotech Resource Hub >>

      • SUBSCRIBE TO OUR BLOG
      • SUBMIT YOUR BLOG POST

      Latest News

      • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
      • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
      • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am

      Categories

      • Bioprocessing
      • Biosafety Testing
      • End-to-End Solutions
      • Frontpage Article
      • Gene Therapy
      • Investigator's Brochure
      • News
      • Uncategorized
      • Vaccines
      • Viral Vectors
      • Webinar

      Archives

      • February 2023
      • January 2023
      • December 2022
      • November 2022
      • October 2022
      • September 2022
      • August 2022
      • July 2022
      • May 2022
      • April 2022
      • March 2022
      • February 2022
      • January 2022
      • November 2021
      • October 2021
      • September 2021
      • August 2021
      • July 2021
      • June 2021
      • May 2021
      • April 2021
      • March 2021
      • February 2021
      • January 2021
      • December 2020
      • November 2020
      • October 2020
      • September 2020
      • August 2020
      • July 2020
      • May 2020
      • April 2020
      • SUBSCRIBE TO OUR BLOG
      • SUBMIT YOUR BLOG POST

      Latest News

      • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
      • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
      • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am

      Categories

      • Bioprocessing
      • Biosafety Testing
      • End-to-End Solutions
      • Frontpage Article
      • Gene Therapy
      • Investigator's Brochure
      • News
      • Uncategorized
      • Vaccines
      • Viral Vectors
      • Webinar

      Archives

      • February 2023
      • January 2023
      • December 2022
      • November 2022
      • October 2022
      • September 2022
      • August 2022
      • July 2022
      • May 2022
      • April 2022
      • March 2022
      • February 2022
      • January 2022
      • November 2021
      • October 2021
      • September 2021
      • August 2021
      • July 2021
      • June 2021
      • May 2021
      • April 2021
      • March 2021
      • February 2021
      • January 2021
      • December 2020
      • November 2020
      • October 2020
      • September 2020
      • August 2020
      • July 2020
      • May 2020
      • April 2020

      Tags

      applications bioprocessing biotech blazar Congratulations Content education Europe FDA Format gene therapy grant grants Investigator's Brochure molecule new NGS Pharmaceuticals program services symposia tags things Tone VAR2 viral assurance viral clearance virus virus detection winner

      Business Hours

      Our support Hotline is available 24 Hours a day: (555) 343 456 7891

      • Monday-Friday: 9am to 5pm
      • Saturday: 10am to 2pm
      • Sunday: Closed

      Latest News

      • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
      • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
      • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am
      • The Future of BiopharmaDecember 6, 2022 - 4:39 am
      • Last chance: 3rd Annual Startup Symposium – Day 3November 10, 2022 - 5:39 am
      • The Lack of Funding for Women Entrepreneurs Doesn’t Stop Them from Launching – But We Still Have a Long Way to Go – And We Can Help Each Other. Assurea is ROOTING FOR YOU!October 21, 2022 - 8:27 am

      Categories

      • Bioprocessing
      • Biosafety Testing
      • End-to-End Solutions
      • Frontpage Article
      • Gene Therapy
      • Investigator's Brochure
      • News
      • Uncategorized
      • Vaccines
      • Viral Vectors
      • Webinar
      • Author
      • Recent Posts
      Charlotte McLure
      Junior Technician at VectorY
      Charlotte is a Junior Technician at VectorY working in the process development team. Her background is in Chemistry and she holds a Master’s in Chemistry with Environmental and Sustainable Chemistry from The University of Edinburgh. The life-sciences world is therefore new to Charlotte, but she has thoroughly enjoyed building up her understanding of gene therapy and of bioprocessing. Originally from Scotland, she loves to ski and to mountain bike. Upon arrival in the flattest country in Europe, she swapped her mountain bike for a race bike and enjoys exploring The Netherlands at great speed in this way. In her free time she likes to dance at festivals and to talk about her cat.
      Latest posts by Charlotte McLure (see all)
        +3
        © 2020 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. | Privacy Policy | Cookie Settings
        Gene Therapy University Discounted Enrollment 5 Minutes Could Mean $255k in Grants!
        Scroll to top

        This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. We use cookies in our website to give you the most relevant experience. By clicking or navigating the site, you are accepting the use of all our cookies according to our Cookie Policy / Privacy Statement. You are free to decide in the Cookie Settings which categories you would like to allow. Please note that depending on what you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Policy

        Accept All CookiesCookie Settings

        Cookie and Privacy Settings



        Cookie Preferences

        When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about how we use and share your data, please follow this link.
        Privacy Statement

        Necessary

        Always Active
        These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.

        Functional

        These cookies enable the provision of advanced functionalities and are used for personalization. The cookies are set in particular in response to your actions and depend on your specific service requests (e.g., pop-up notification choices).Changes will take effect once you reload the page.

        Targeting

        These cookies may be set to learn more about your interests and show you relevant ads on other websites. These cookies work by uniquely identifying your browser and device. By integrating these cookies, we aim to learn more about your interests and your surfing behavior and to be able to place our advertising in a targeted manner.

        Confirm My ChoicesAllow AllDisable All

        loading

        Please wait while you are redirected to the right page...

        Please share your location to continue.

        Check our help guide for more info.

        share your location